1-3 of 3
Alan Xiao, PhD
Close
Sort by
Journal Articles

MK-0457, a Novel Aurora Kinase and BCR-ABL Inhibitor, Is Active Against BCR-ABL T315I Mutant Chronic Myelogenous Leukemia (CML).

Francis Giles, MD, Jorge Cortes, MD, Donald A. Bergstrom, MD, PhD, Alan Xiao, PhD, Penny Bristow, Dan Jones, MD, PhD, Srdan Verstovsek, MD, PhD, Deborah Thomas, MD, Hagop Kantarjian, MD, Steven J. Freedman, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 163.
https://doi.org/10.1182/blood.V108.11.163.163
Published: 2006
Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

Francis Giles, MD, Jorge Cortes, MD, Donald A. Bergstrom, MD, PhD, Alan Xiao, PhD, Dan Jones, MD, PhD, Srdan Verstovsek, MD, PhD, Deborah Thomas, MD, Hagop M. Kantarjian, MD, Steven J. Freedman, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 253.
https://doi.org/10.1182/blood.V108.11.253.253
Published: 2006
Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Inhibits BCR-ABL Activity in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Mutation.

Donald A. Bergstrom, MD, PhD, Jason B. Clark, PhD, Alan Xiao, PhD, Matthew Griffiths, PhD, Susannah Falcon, PhD, John Pollard, PhD, Steven J. Freedman, MD,PhD, Francis Giles, MD
Journal: Blood
Blood (2006) 108 (11): 637.
https://doi.org/10.1182/blood.V108.11.637.637
Published: 2006